AVITA Medical (RCEL) grants options and RSUs to Chief Legal Officer

Rhea-AI Filing Summary

AVITA Medical, Inc. reported that Chief Legal Officer Nicole Kelsey received equity awards consisting of stock options and restricted stock units. She was granted stock options for 145,060 shares at an exercise price of $0.0000 per share and 98,390 shares of Common Stock through restricted stock units.

The restricted stock units each represent the right to receive one share of Common Stock and vest in three equal annual installments beginning 12 months after the February 18, 2026 grant date. The stock options vest in three equal annual installments beginning on the first anniversary of the February 18, 2026 grant date, aligning the awards with multi-year service and performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KELSEY NICOLE

(Last) (First) (Middle)

C/O AVITA MEDICAL, INC.

28159 AVENUE STANFORD, SUITE 200

(Street)

VALENCIA CA 91355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		A		98,390	A	(1)	98,390(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$4.31	02/18/2026		A		145,060		(3)	02/18/2036	Common Stock	145,060	$0	145,060	D

Explanation of Responses:

1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date of February 18, 2026.

2. Includes unvested RSUs.

3. These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date of February 18, 2026.

	/s/ Nicole Kelsey	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AVITA Medical (RCEL) report for Nicole Kelsey?

AVITA Medical reported that Chief Legal Officer Nicole Kelsey acquired equity awards through grants, not open-market purchases. She received stock options and restricted stock units under company compensation, reflecting non-cash incentive awards tied to continued service and time-based vesting conditions over several years.

How many stock options were granted to Nicole Kelsey at AVITA Medical (RCEL)?

Nicole Kelsey was granted stock options covering 145,060 shares of AVITA Medical Common Stock. These options have an exercise price of $0.0000 per share and vest in three equal annual installments, starting on the first anniversary of the February 18, 2026 grant date.

What restricted stock unit award did Nicole Kelsey receive from AVITA Medical (RCEL)?

She received an award of 98,390 restricted stock units, each representing a contingent right to one AVITA Medical Common share. These RSUs are subject to time-based vesting, in three equal annual installments beginning 12 months after the February 18, 2026 grant date.

Are Nicole Kelsey’s AVITA Medical (RCEL) equity awards immediately vested?

No, both the restricted stock units and stock options are subject to time-based vesting. The RSUs vest in three equal annual installments starting 12 months after grant, while the options vest in three equal annual installments from the first grant anniversary.

Does Nicole Kelsey’s Form 4 for AVITA Medical (RCEL) involve any stock sales?

The Form 4 shows only grant or award acquisitions, not sales. It reports awards of stock options and restricted stock units at an exercise price of $0.0000, reflecting compensation rather than any disposition of AVITA Medical Common Stock.

What does “Includes unvested RSUs” mean in Nicole Kelsey’s AVITA Medical (RCEL) holdings?

The phrase indicates that the reported total Common Stock-related holdings for Nicole Kelsey include restricted stock units that have not yet vested. These unvested RSUs still depend on satisfying future time-based vesting conditions before shares are actually delivered.